Business
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation ArmAt Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fF5s8tDZfOcdddQ1DBkmiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fF5s8tDZfOcdddQ1DBkmiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL)","length":213,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation Arm","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"At Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation Arm","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable Safety Profile with No CRS, ICANS, GvHD, or Treatment-Related Serious Adverse Events or Hospitalizations, Enabling Majority Outpatient Management","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Approximately One-Third of Screening Activity and Cema-Cel Infusions Occurred at Community Cancer Centers, Including Sites New to CAR T Therapy","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Site Activation and Patient Screening Underway in South Korea and Australia","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Interim Event-Free Survival (EFS) Analysis Expected Mid-2027","length":60,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":722,"olType":false}]},{"val":[{"type":"text","content":"Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease Continues Dose Escalation","le...